Oligoastrocytoma natural history, complications and prognosis: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
Line 28: Line 28:
*Depending on the extent and grade of the tumor at the time of diagnosis, the prognosis of oligoastrocytoma may vary.  However, the prognosis is generally regarded as good.
*Depending on the extent and grade of the tumor at the time of diagnosis, the prognosis of oligoastrocytoma may vary.  However, the prognosis is generally regarded as good.
*Oligodendrogliomas are slowly growing tumors with prolonged survival. The [[median]] survival time for oligodendroglioma is 11.6 years for grade II and 3.5 years for grade III.
*Oligodendrogliomas are slowly growing tumors with prolonged survival. The [[median]] survival time for oligodendroglioma is 11.6 years for grade II and 3.5 years for grade III.
*The presence of 1p19q codeletion is associated with a better prognosis and greater chemosensitivity.<ref name=patho1>Pathology of oligoastrocytoma. Dr Bruno Di Muzio and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/oligoastrocytoma. Accessed on October 16, 2015</ref>
*The 1, 5, and 10-year survival rates of patients with oligoastrocytoma are approximately 87%, 56.97%, and 45.80%.<ref name=cbtrus3> One–, Two–, Three–, Four–, Five–, and 10–year relative survival rates for selected malignant brain and central nervous system tumors, Seer 17 Registries, 1995-2006. CBTRUS 2015. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf. Accessed on October 16, 2015</ref>
*The 1, 5, and 10-year survival rates of patients with oligoastrocytoma are approximately 87%, 56.97%, and 45.80%.<ref name=cbtrus3> One–, Two–, Three–, Four–, Five–, and 10–year relative survival rates for selected malignant brain and central nervous system tumors, Seer 17 Registries, 1995-2006. CBTRUS 2015. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf. Accessed on October 16, 2015</ref>
*Favorable prognostic factors include:<ref name=patho1>Pathology of oligoastrocytoma. Dr Bruno Di Muzio and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/oligoastrocytoma. Accessed on October 16, 2015</ref><ref name="pmid15026604">{{cite journal| author=Naugle DK, Duncan TD, Grice GP| title=Oligoastrocytoma. | journal=Radiographics | year= 2004 | volume= 24 | issue= 2 | pages= 598-600 | pmid=15026604 | doi=10.1148/rg.242035069 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15026604  }} </ref>
*Presence of 1p19q codeletion
*Age at presentation < 40 years
*Lower grade of [[tumor]]
*Extent of er[[surgery|surgical resection]]


==References==
==References==

Revision as of 21:58, 16 October 2015

Oligodendroglioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Oligodendroglioma from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications, and Prognosis

Diagnosis

Staging

History & Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Oligoastrocytoma natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Oligoastrocytoma natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Oligoastrocytoma natural history, complications and prognosis

CDC on Oligoastrocytoma natural history, complications and prognosis

Oligoastrocytoma natural history, complications and prognosis in the news

Blogs on Oligoastrocytoma natural history, complications and prognosis

Directions to Hospitals Treating Oligodendroglioma

Risk calculators and risk factors for Oligoastrocytoma natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2]

Overview

If left untreated, patients with oligodendroglioma may progress to develop seizures, focal neurological deficits, hydrocephalus, brain herniation, intracranial hemorrhage, and ultimately death.[1] Common complications associated with oligodendroglioma include hydrocephalus, intracranial hemorrhage, coma, bone marrow metastasis, recurrence, venous thromboembolism, parkinsonism, and side effects of chemotherapy and radiotherapy.[2][3][4][5][6][7][8] Depending on the extent and grade of the tumor at the time of diagnosis, the prognosis of oligodendroglioma may vary. However, the prognosis is generally regarded as good. The median survival time for oligodendroglioma is 11.6 years for grade II and 3.5 years for grade III.[9]

Natural history

  • Oligodendrogliomas tend to be low grade and less aggressive than other types of gliomas. These tumors are slow growing. The tumors may be present for many years before they are diagnosed.[10]
  • Anaplastic oligodendroglioma usually grows quickly. These tumors may develop in one place or in many places throughout the brain.
  • If left untreated, patients with oligodendroglioma may progress to develop seizures, focal neurological deficits, hydrocephalus, brain herniation, intracranial hemorrhage, and ultimately death.[1]
  • Recurrence is a very common feature of oligodendrogliomas. It can be either of the same grade or higher grade at the primary site.[11]
  • Transformation into glioblastoma (grade 4) may occur a few years later, which may be associated with gain of chromosome 7 and loss of chromosome 10.[11]

Complications

Common complications associated with oligodendroglioma include:[2][3][4][5][6][7][8]

Prognosis

  • Depending on the extent and grade of the tumor at the time of diagnosis, the prognosis of oligoastrocytoma may vary. However, the prognosis is generally regarded as good.
  • Oligodendrogliomas are slowly growing tumors with prolonged survival. The median survival time for oligodendroglioma is 11.6 years for grade II and 3.5 years for grade III.
  • The 1, 5, and 10-year survival rates of patients with oligoastrocytoma are approximately 87%, 56.97%, and 45.80%.[12]
  • Favorable prognostic factors include:[13][14]
  • Presence of 1p19q codeletion
  • Age at presentation < 40 years
  • Lower grade of tumor
  • Extent of ersurgical resection

References

  1. ↑ 1.0 1.1 Manousaki M, Papadaki H, Papavdi A, Kranioti EF, Mylonakis P, Varakis J; et al. (2011). "Sudden unexpected death from oligodendroglioma: a case report and review of the literature". Am J Forensic Med Pathol. 32 (4): 336–40. doi:10.1097/PAF.0b013e3181d3dc86. PMID 20375839.
  2. ↑ 2.0 2.1 Simonetti G, Gaviani P, Botturi A, Innocenti A, Lamperti E, Silvani A (2015). "Clinical management of grade III oligodendroglioma". Cancer Manag Res. 7: 213–23. doi:10.2147/CMAR.S56975. PMC 4524382. PMID 26251628.
  3. ↑ 3.0 3.1 Guppy KH, Akins PT, Moes GS, Prados MD (2009). "Spinal cord oligodendroglioma with 1p and 19q deletions presenting with cerebral oligodendrogliomatosis". J Neurosurg Spine. 10 (6): 557–63. doi:10.3171/2009.2.SPINE08853. PMID 19558288.
  4. ↑ 4.0 4.1 Sharma A, Agarwal A, Sharma MC, Anand M, Agarwal S, Raina V (2003). "Bone marrow metastasis in anaplastic oligodendroglioma". Int J Clin Pract. 57 (4): 351–2. PMID 12800473.
  5. ↑ 5.0 5.1 Solitare GB, Robinson F, Lamarche JB (1967). "Oligodendroglioma: recurrence following an exceptionally long postoperative symptom-free interval". Can Med Assoc J. 97 (14): 862–5. PMC 1923454. PMID 6051252.
  6. ↑ 6.0 6.1 Harada K, Kiya K, Matsumura S, Mori S, Uozumi T (1982). "Spontaneous intracranial hemorrhage caused by oligodendroglioma--a case report and review of the literature". Neurol Med Chir (Tokyo). 22 (1): 81–4. PMID 6176898.
  7. ↑ 7.0 7.1 Hentschel S, Toyota B (2003). "Intracranial malignant glioma presenting as subarachnoid hemorrhage". Can J Neurol Sci. 30 (1): 63–6. PMID 12619787.
  8. ↑ 8.0 8.1 Krauss JK, Paduch T, Mundinger F, Seeger W (1995). "Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia". Acta Neurochir (Wien). 133 (1–2): 22–9. PMID 8561031.
  9. ↑ Ohgaki H, Kleihues P (2005). "Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas". J Neuropathol Exp Neurol. 64 (6): 479–89. PMID 15977639.
  10. ↑ Survival by prognostic factors. Canadian Cancer Society 2015. http://www.cancer.ca/en/cancer-information/cancer-type/brain-spinal/prognosis-and-survival/survival-statistics/?region=on
  11. ↑ 11.0 11.1 Kocaeli H, Yakut T, Bekar A, Taşkapilioğlu O, Tolunay S (2006). "Glioblastomatous recurrence of oligodendroglioma remote from the original site: a case report". Surg Neurol. 66 (6): 627–30, discussion 630-1. doi:10.1016/j.surneu.2006.02.049. PMID 17145331.
  12. ↑ One–, Two–, Three–, Four–, Five–, and 10–year relative survival rates for selected malignant brain and central nervous system tumors, Seer 17 Registries, 1995-2006. CBTRUS 2015. http://www.cbtrus.org/2010-NPCR-SEER/CBTRUS-WEBREPORT-Final-3-2-10.pdf. Accessed on October 16, 2015
  13. ↑ Pathology of oligoastrocytoma. Dr Bruno Di Muzio and Dr Frank Gaillard et al. Radiopaedia 2015. http://radiopaedia.org/articles/oligoastrocytoma. Accessed on October 16, 2015
  14. ↑ Naugle DK, Duncan TD, Grice GP (2004). "Oligoastrocytoma". Radiographics. 24 (2): 598–600. doi:10.1148/rg.242035069. PMID 15026604.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Oligoastrocytoma_natural_history,_complications_and_prognosis&oldid=1176327"